UNSPSC 51281802: Aclarubicin or aclacinomycin A

This classification denotes an aclacinomycin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74KXF8I502. European Medicines Agency schedules Aclarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05243MIG. Aclarubicin generally arises in the molecular formula C42H53NO15. The term ACLARUBICIN is an International Non-Proprietary Name or INN. ACLARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

SMILES: O(C1CC(O)(C(C2C1C(O)C1C(C2)C(=O)C2C(C1=O)C(O)CCC2)C(=O)OC)CC)C1OC(C(OC2OC(C(OC3OC(C(=O)CC3)C)C(O)C2)C)C(N(C)C)C1)C.

UNSPSC 51281802 Aclarubicin or aclacinomycin A is a Commodity code that shows minimal recent alignment with state and local procurement activity. The two most recent opportunities posted under this code—a pharmaceutical warehouse order from the Illinois Department of Public Health and a naloxone/drug deactivation systems procurement from Seminole County, Florida—do not match the code's nominal scope of aclarubicin or aclacinomycin A, both of which are oncology chemotherapy agents. The Illinois contract, awarded to Chartwell Rx LLC on August 28, 2026, supplies Doxycycline Hyclate and Ciprofloxacin Hydrochloride through an MMCAP piggyback vehicle with a total award of $2,999,999.11 over three years; the Seminole County solicitation (IFB 60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems for community health purposes. Neither opportunity reflects procurement of aclarubicin or aclacinomycin A as the code defines it.

State and local procurement activity under this code appears limited or mislabeled. If aclarubicin or aclacinomycin A is being procured by state agencies or health systems, it would likely flow through existing oncology or hospital formulary contracts rather than standalone solicitations. Business development professionals targeting this code should verify whether state hospital networks, cancer centers, or state health departments maintain active demand before investing pursuit resources; the available record does not support material recent opportunities in this commodity.